GT Biopharma (OTCMKTS:GTBP – Get Rating) had its price objective reduced by HC Wainwright from $25.00 to $5.00 in a research note issued to investors on Tuesday, The Fly reports. They currently have a buy rating on the stock.
Separately, Roth Capital lowered shares of GT Biopharma from a buy rating to a neutral rating in a research report on Thursday, August 11th.
GT Biopharma Price Performance
Shares of GT Biopharma stock opened at $2.20 on Tuesday. GT Biopharma has a 1 year low of $1.51 and a 1 year high of $8.28. The firm has a market cap of $68.40 million, a PE ratio of -2.29 and a beta of 0.54. The company has a 50 day simple moving average of $2.70 and a two-hundred day simple moving average of $2.68.
Institutional Inflows and Outflows
About GT Biopharma
GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.
- Get a free copy of the StockNews.com research report on GT Biopharma (GTBP)
- Is Five Below Trying to Punch Too High?
- These 3 Reports Will Tell Us Much About the Current Economy
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle’s FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.